1
|
Lipiński PFJ, Matalińska J. Fentanyl Structure as a Scaffold for Opioid/Non-Opioid Multitarget Analgesics. Int J Mol Sci 2022; 23:ijms23052766. [PMID: 35269909 PMCID: PMC8910985 DOI: 10.3390/ijms23052766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Revised: 02/28/2022] [Accepted: 03/01/2022] [Indexed: 11/16/2022] Open
Abstract
One of the strategies in the search for safe and effective analgesic drugs is the design of multitarget analgesics. Such compounds are intended to have high affinity and activity at more than one molecular target involved in pain modulation. In the present contribution we summarize the attempts in which fentanyl or its substructures were used as a μ-opioid receptor pharmacophoric fragment and a scaffold to which fragments related to non-opioid receptors were attached. The non-opioid ‘second’ targets included proteins as diverse as imidazoline I2 binding sites, CB1 cannabinoid receptor, NK1 tachykinin receptor, D2 dopamine receptor, cyclooxygenases, fatty acid amide hydrolase and monoacylglycerol lipase and σ1 receptor. Reviewing the individual attempts, we outline the chemistry, the obtained pharmacological properties and structure-activity relationships. Finally, we discuss the possible directions for future work.
Collapse
|
2
|
Novel NK1R-Targeted 68Ga-/ 177Lu-Radioconjugates with Potential Application against Glioblastoma Multiforme: Preliminary Exploration of Structure-Activity Relationships. Int J Mol Sci 2022; 23:ijms23031214. [PMID: 35163139 PMCID: PMC8835841 DOI: 10.3390/ijms23031214] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 01/14/2022] [Accepted: 01/18/2022] [Indexed: 02/06/2023] Open
Abstract
Locoregionally administered, NK1 receptor (NK1R) targeted radionuclide therapy is a promising strategy for the treatment of glioblastoma multiforme. So far, the radiopharmaceuticals used in this approach have been based on the endogenous agonist of NK1R, Substance P or on its close analogues. Herein, we used a well-known, small molecular NK1R antagonist, L732,138, as the basis for the radiopharmaceutical vector. First, 14 analogues of this compound were evaluated to check whether extending the parent structure with linkers of different lengths would not deteriorate the NK1R binding. The tested analogues had affinity similar to or better than the parent compound, and none of the linkers had a negative impact on the binding. Next, five DOTA conjugates were synthesized and used for labelling with 68Ga and 177Lu. The obtained radioconjugates turned out to be fairly lipophilic but showed rather limited stability in human plasma. Evaluation of the receptor affinity of the (radio)conjugates showed that neither the chelator nor the metal negatively impacts the NK1R binding. The 177Lu-radioconjugates exhibited the binding characteristics towards NK1R similar or better than that of the 177Lu-labelled derivative of Substance P, which is in current clinical use. The experimental results presented herein, along with their structural rationalization provided by modelling, give insight for the further molecular design of small molecular NK1R-targeting vectors.
Collapse
|
3
|
Liu L, Grillo F, Canfarotta F, Whitcombe M, Morgan SP, Piletsky S, Correia R, He C, Norris A, Korposh S. Carboxyl-fentanyl detection using optical fibre grating-based sensors functionalised with molecularly imprinted nanoparticles. Biosens Bioelectron 2021; 177:113002. [PMID: 33486137 DOI: 10.1016/j.bios.2021.113002] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Revised: 01/05/2021] [Accepted: 01/12/2021] [Indexed: 01/03/2023]
Abstract
Butyrylfentanyl is a new designer drug reported with growing use and related deaths. Routine toxicological analyses of this novel synthetic opioid drug have not been established yet. This work reports a fibre optic sensor that measures carboxyl-fentanyl which is the major metabolite of butyrylfentanyl presented in blood, providing a promising tool for detecting butyrylfentanyl intoxication. A long period fibre grating (LPG) sensor array operating at phase-matching condition is deployed in combination with a state-of-the-art molecular imprinting technique. Nano-sized molecularly imprinted polymers (nanoMIPs) are synthesised via a solid-phase approach and coated on the surface of an LPG array. An LPG array consists of two parts: a detection and a reference LPG. The former is functionalised with nanoMIPs prior to the measurements, whilst the latter is used to take into account the temperature response of the detection LPG. The developed sensor exhibits a gradual response over increasing concentrations of carboxyl-fentanyl from 0 to 1000 ng/mL with a minimal detected concentration of 50 ng/mL, that corresponds to a wavelength shift of 1.20 ± 0.2 nm. The Langmuir adsorption isotherm is applied to fit the analytical data which reveal a binding constant of 2.03 μM-1. The developed sensor shows high selectivity in detecting carboxyl-fentanyl among other drugs and potential interferents including morphine, cocaine, glucose and albumin. It shows a certain degree of cross-response to fentanyl which shares the same binding sites as carboxyl-fentanyl and therefore can be potentially used to detect fentanyl.
Collapse
Affiliation(s)
- LiangLiang Liu
- Optics and Photonics Group, University of Nottingham, Nottingham, UK
| | - Fabiana Grillo
- Department of Chemistry, University of Leicester, Leicester, UK
| | | | | | - Stephen P Morgan
- Optics and Photonics Group, University of Nottingham, Nottingham, UK
| | - Sergey Piletsky
- Department of Chemistry, University of Leicester, Leicester, UK
| | - Ricardo Correia
- Optics and Photonics Group, University of Nottingham, Nottingham, UK
| | - ChenYang He
- Optics and Photonics Group, University of Nottingham, Nottingham, UK
| | - Andrew Norris
- Department of Anesthesiology, Nottingham University Hospitals NHS Trust, Nottingham, UK; Department of Anesthesiology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
| | - Serhiy Korposh
- Optics and Photonics Group, University of Nottingham, Nottingham, UK.
| |
Collapse
|
4
|
Balalaie S, Malakoutikhah M, Teixidó M, Fathi Vavsari V, Giralt E, Haghighatnia Y, Hamdan F, Arabanian A. Efficient Synthesis of Norbuprenorphines Coupled with Enkephalins and Investigation of Their Permeability. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH : IJPR 2020; 18:1277-1287. [PMID: 32641938 PMCID: PMC6934973 DOI: 10.22037/ijpr.2019.14712.12602] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
An efficient approach for the synthesis of norbuprenorphin derivatives through coupling of enkephalins and norbuprenorphine intermediates is described. Norbuprenorphine derivative was synthesized from thebaine and then, its reaction with succinic acid and phthalic acid was also studied. Meanwhile, the synthesis of enkephalins was done using solid phase peptide synthesis approach. Furthermore, after cleavage of the peptide from the surface of the resin, the coupling of enkephalins with norbuprenorphine derivative was done using TBTU as a coupling reagent then the derivatives were purified using preparative high-pressure liquid chromatography and their structures were confirmed using high-resolution mass spectrometry data. Later, their permeability across membranes was investigated. After PAMPA studies, it was found that the permeability of all norbuprenorphin-enkephalin derivatives was increased; however, succinic and phthalic acid derivatives showed higher permeability than norbuprenorphine-Leu-enkephalin.
Collapse
Affiliation(s)
- Saeed Balalaie
- Peptide Chemistry Research Center, K. N. Toosi University of Technology, Tehran, Iran.,Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Morteza Malakoutikhah
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Baldiri Reixac 10, 08028 Barcelona, Spain
| | - Meritxell Teixidó
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Baldiri Reixac 10, 08028 Barcelona, Spain
| | - Vaezeh Fathi Vavsari
- Peptide Chemistry Research Center, K. N. Toosi University of Technology, Tehran, Iran
| | - Ernest Giralt
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Baldiri Reixac 10, 08028 Barcelona, Spain
| | - Yaghoub Haghighatnia
- Peptide Chemistry Research Center, K. N. Toosi University of Technology, Tehran, Iran
| | - Fatima Hamdan
- Peptide Chemistry Research Center, K. N. Toosi University of Technology, Tehran, Iran
| | - Armin Arabanian
- Peptide Chemistry Research Center, K. N. Toosi University of Technology, Tehran, Iran
| |
Collapse
|
5
|
Abstract
Hybrid compounds (also known as chimeras, designed multiple ligands, bivalent compounds) are chemical units where two active components, usually possessing affinity and selectivity for distinct molecular targets, are combined as a single chemical entity. The rationale for using a chimeric approach is well documented as such novel drugs are characterized by their enhanced enzymatic stability and biological activity. This allows their use at lower concentrations, increasing their safety profile, particularly when considering undesirable side effects. In the group of synthetic bivalent compounds, drugs combining pharmacophores having affinities toward opioid and neurokinin-1 receptors have been extensively studied as potential analgesic drugs. Indeed, substance P is known as a major endogenous modulator of nociception both in the peripheral and central nervous systems. Hence, synthetic peptide fragments showing either agonism or antagonism at neurokinin 1 receptor were both assigned with analgesic properties. However, even though preclinical studies designated neurokinin-1 receptor antagonists as promising analgesics, early clinical studies revealed a lack of efficacy in human. Nevertheless, their molecular combination with enkephalin/endomorphin fragments has been considered as a valuable approach to design putatively promising ligands for the treatment of pain. This paper is aimed at summarizing a 20-year journey to the development of potent analgesic hybrid compounds involving an opioid pharmacophore and devoid of unwanted side effects. Additionally, the legitimacy of considering neurokinin-1 receptor ligands in the design of chimeric drugs is discussed.
Collapse
|
6
|
Golmohammadi F, Balalaie S, Hamdan F, Maghari S. Efficient synthesis of novel conjugated 1,3,4-oxadiazole–peptides. NEW J CHEM 2018. [DOI: 10.1039/c7nj04720g] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
In this study, we developed an efficient approach for the synthesis of 2-amino-1,3,4-oxadiazoles that are bioisosteres of the amide functional group. The synthesized oxadiazoles were conjugated to octa- and nonapeptides through the C- or N-terminus as precursors of leuprolide acetate. The synthesized compounds are peptidomimetics of leuprolide acetate.
Collapse
Affiliation(s)
- Farhad Golmohammadi
- Peptide Chemistry Research Center
- K. N. Toosi University of Technology
- Tehran
- Iran
| | - Saeed Balalaie
- Peptide Chemistry Research Center
- K. N. Toosi University of Technology
- Tehran
- Iran
- Medical Biology Research Center
| | - Fatima Hamdan
- Peptide Chemistry Research Center
- K. N. Toosi University of Technology
- Tehran
- Iran
| | - Shokoofeh Maghari
- Peptide Chemistry Research Center
- K. N. Toosi University of Technology
- Tehran
- Iran
| |
Collapse
|
7
|
Olson KM, Lei W, Keresztes A, LaVigne J, Streicher JM. Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain. THE YALE JOURNAL OF BIOLOGY AND MEDICINE 2017; 90:97-110. [PMID: 28356897 PMCID: PMC5369049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Opioid drugs like morphine and fentanyl are the gold standard for treating moderate to severe acute and chronic pain. However, opioid drug use can be limited by serious side effects, including constipation, tolerance, respiratory suppression, and addiction. For more than 100 years, we have tried to develop opioids that decrease or eliminate these liabilities, with little success. Recent advances in understanding opioid receptor signal transduction have suggested new possibilities to activate the opioid receptors to cause analgesia, while reducing or eliminating unwanted side effects. These new approaches include designing functionally selective ligands, which activate desired signaling cascades while avoiding signaling cascades that are thought to provoke side effects. It may also be possible to directly modulate downstream signaling through the use of selective activators and inhibitors. Separate from downstream signal transduction, it has also been found that when the opioid system is stimulated, various negative feedback systems are upregulated to compensate, which can drive side effects. This has led to the development of multi-functional molecules that simultaneously activate the opioid receptor while blocking various negative feedback receptor systems including cholecystokinin and neurokinin-1. Other novel approaches include targeting heterodimers of the opioid and other receptor systems which may drive side effects, and making endogenous opioid peptides druggable, which may also reduce opioid mediated side effects. Taken together, these advances in our molecular understanding provide a path forward to break the barrier in producing an opioid with reduced or eliminated side effects, especially addiction, which may provide relief for millions of patients.
Collapse
Affiliation(s)
- Keith M. Olson
- Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ,Department of Chemistry and Biochemistry, College of Science, University of Arizona, Tucson, AZ
| | - Wei Lei
- Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ
| | - Attila Keresztes
- Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ
| | - Justin LaVigne
- Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ
| | - John M. Streicher
- Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ,To whom all correspondence should be addressed: John M. Streicher, Ph.D., University of Arizona, College of Medicine, Department of Pharmacology, Life Sciences North 563, Box 245050, 1501 N. Campbell Ave., Tucson, AZ 85724, 520-626-7495,
| |
Collapse
|
8
|
Vardanyan RS, Cain JP, Haghighi SM, Kumirov VK, McIntosh MI, Sandweiss AJ, Porreca F, Hruby VJ. Synthesis and Investigation of Mixed μ-Opioid and δ-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain. J Heterocycl Chem 2017; 54:1228-1235. [PMID: 28819330 PMCID: PMC5557416 DOI: 10.1002/jhet.2696] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Several studies have suggested functional association between μ-opioid and δ-opioid receptors and showed that μ-activity could be modulated by δ-ligands. The general conclusion is that agonists for the δ-receptor can enhance the analgesic potency and efficacy of μ-agonists. Our preliminary investigations demonstrate that new bivalent ligands constructed from the μ-agonist fentanyl and the δ-agonist enkephalin-like peptides are promising entities for creation of new analgesics with reduced side effects for treatment of neuropathic pain. A new superposition of the mentioned pharmacophores led to novel μ-bivalent/δ-bivalent compounds that demonstrate both μ-opioid and δ-opioid receptor agonist activity and high efficacy in anti-inflammatory and neuropathic pain models with the potential of reduced unwanted side effects.
Collapse
Affiliation(s)
- Ruben S. Vardanyan
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, US
| | - James P. Cain
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, US
| | | | - Vlad K. Kumirov
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, US
| | - Mary I. McIntosh
- Department of Pharmacology, University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
| | - Alexander J. Sandweiss
- Department of Pharmacology, University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
| | - Frank Porreca
- Department of Pharmacology, University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
| | - Victor J. Hruby
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, US
| |
Collapse
|
9
|
Li S, Cohen-Karni D, Kovaliov M, Tomycz N, Cheng B, Whiting D, Averick S. Synthesis and biological evaluation of fentanyl acrylic derivatives. RSC Adv 2017. [DOI: 10.1039/c7ra01346a] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Synthesis and biological evaluation of fentanyl acrylic derivatives.
Collapse
Affiliation(s)
- Shaohua Li
- Neuroscience Disruptive Research Lab
- Allegheny Health Network Research Institute
- Allegheny General Hospital
- Pittsburgh
- USA
| | - Devora Cohen-Karni
- Neuroscience Disruptive Research Lab
- Allegheny Health Network Research Institute
- Allegheny General Hospital
- Pittsburgh
- USA
| | - Marina Kovaliov
- Neuroscience Disruptive Research Lab
- Allegheny Health Network Research Institute
- Allegheny General Hospital
- Pittsburgh
- USA
| | - Nestor Tomycz
- Neuroscience Institute
- Allegheny Health Network
- Allegheny General Hospital
- Pittsburgh
- USA
| | - Boyle Cheng
- Neuroscience Institute
- Allegheny Health Network
- Allegheny General Hospital
- Pittsburgh
- USA
| | - Donald Whiting
- Neuroscience Institute
- Allegheny Health Network
- Allegheny General Hospital
- Pittsburgh
- USA
| | - Saadyah Averick
- Neuroscience Disruptive Research Lab
- Allegheny Health Network Research Institute
- Allegheny General Hospital
- Pittsburgh
- USA
| |
Collapse
|
10
|
Gomes I, Sierra S, Devi LA. Detection of Receptor Heteromerization Using In Situ Proximity Ligation Assay. CURRENT PROTOCOLS IN PHARMACOLOGY 2016; 75:2.16.1-2.16.31. [PMID: 27960030 PMCID: PMC5758307 DOI: 10.1002/cpph.15] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Although G protein-coupled receptor (GPCR) heteromerization has been extensively demonstrated in vitro using heterologous cells that overexpress epitope-tagged receptors, their presence in endogenous systems is less well established. This is because a criterion to identify receptor heteromerization is the demonstration that the two interacting receptors are present not only in the same cell but also in the same subcellular compartment in close enough proximity to allow for direct receptor-receptor interaction. This has been difficult to study in native tissues due to a lack of sensitive and selective tools not only capable of detecting low-abundance proteins but also of demonstrating that they are in sufficiently close proximity to interact. The latter can be achieved using a proximity ligation assay (PLA). Detailed in this unit are protocols for demonstrating the presence of GPCR heteromers in endogenous cells as well as animal and human tissues, the controls required for these assays, and troubleshooting tips. © 2016 by John Wiley & Sons, Inc.
Collapse
Affiliation(s)
- Ivone Gomes
- Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Salvador Sierra
- Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Lakshmi A Devi
- Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
| |
Collapse
|
11
|
Bremer PT, Kimishima A, Schlosburg JE, Zhou B, Collins KC, Janda KD. Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs. Angew Chem Int Ed Engl 2016; 55:3772-5. [PMID: 26879590 PMCID: PMC4860013 DOI: 10.1002/anie.201511654] [Citation(s) in RCA: 104] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2015] [Revised: 01/22/2015] [Indexed: 11/08/2022]
Abstract
Fentanyl is an addictive prescription opioid that is over 80 times more potent than morphine. The synthetic nature of fentanyl has enabled the creation of dangerous "designer drug" analogues that escape toxicology screening, yet display comparable potency to the parent drug. Alarmingly, a large number of fatalities have been linked to overdose of fentanyl derivatives. Herein, we report an effective immunotherapy for reducing the psychoactive effects of fentanyl class drugs. A single conjugate vaccine was created that elicited high levels of antibodies with cross-reactivity for a wide panel of fentanyl analogues. Moreover, vaccinated mice gained significant protection from lethal fentanyl doses. Lastly, a surface plasmon resonance (SPR)-based technique was established enabling drug-specificity profiling of antibodies derived directly from serum. Our newly developed fentanyl vaccine and analytical methods may assist in the battle against synthetic opioid abuse.
Collapse
Affiliation(s)
- Paul T Bremer
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 N Torrey Pines Rd BCC-582, La Jolla, CA, 92037, USA
| | - Atsushi Kimishima
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 N Torrey Pines Rd BCC-582, La Jolla, CA, 92037, USA
| | - Joel E Schlosburg
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 N Torrey Pines Rd BCC-582, La Jolla, CA, 92037, USA
| | - Bin Zhou
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 N Torrey Pines Rd BCC-582, La Jolla, CA, 92037, USA
| | - Karen C Collins
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 N Torrey Pines Rd BCC-582, La Jolla, CA, 92037, USA
| | - Kim D Janda
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 N Torrey Pines Rd BCC-582, La Jolla, CA, 92037, USA.
| |
Collapse
|
12
|
Bremer PT, Kimishima A, Schlosburg JE, Zhou B, Collins KC, Janda KD. Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs. Angew Chem Int Ed Engl 2016. [DOI: 10.1002/ange.201511654] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Paul T. Bremer
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine (WIRM); The Scripps Research Institute; 10550 N Torrey Pines Rd BCC-582 La Jolla CA 92037 USA
| | - Atsushi Kimishima
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine (WIRM); The Scripps Research Institute; 10550 N Torrey Pines Rd BCC-582 La Jolla CA 92037 USA
| | - Joel E. Schlosburg
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine (WIRM); The Scripps Research Institute; 10550 N Torrey Pines Rd BCC-582 La Jolla CA 92037 USA
| | - Bin Zhou
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine (WIRM); The Scripps Research Institute; 10550 N Torrey Pines Rd BCC-582 La Jolla CA 92037 USA
| | - Karen C. Collins
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine (WIRM); The Scripps Research Institute; 10550 N Torrey Pines Rd BCC-582 La Jolla CA 92037 USA
| | - Kim D. Janda
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine (WIRM); The Scripps Research Institute; 10550 N Torrey Pines Rd BCC-582 La Jolla CA 92037 USA
| |
Collapse
|
13
|
Xiao J, Zeng S, Wang X, Babazada H, Li Z, Liu R, Yu W. Neurokinin 1 and opioid receptors: relationships and interactions in nervous system. TRANSLATIONAL PERIOPERATIVE AND PAIN MEDICINE 2016; 1:11-21. [PMID: 28409174 PMCID: PMC5388438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Opioid receptors and neurokinin 1 receptor (NK1R) are found highly expressed in the central nervous system. The co-localization of these two kinds of receptors suggests that they might interact with each other in both the transmission and modulation of the pain signal. In this review, we explore the relationships between opioid receptors and NK1R. Substance P (SP) plays a modulatory role in the pain transmission by activating the NK1R. Opioid receptor activation can inhibit SP release. NK1R is found participating in the mechanisms of the side effects of the opioids, including opioid analgesic tolerance, hyperalgesia, anxiety behaviors of morphine reward and opioids related respiratory depression. A series of compounds such as NK1R antagonists and ligands works on both mu/delta opioid receptor (MOR/DOR) and NK1R were synthesized as novel analgesics that enhance the clinical pain management efficacy and reduce the dosage and side effects. The current status of these novel ligands and the limitations are discussed in this review. Although the working mechanisms of these ligands remained unclear, they could be used as research tool for developing novel analgesic drugs in the future.
Collapse
Affiliation(s)
- Jie Xiao
- Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University
- Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania
| | - Si Zeng
- Department of Anesthesiology, Sichuan Academy of Medical Science & Sichuan Provincial People’s Hospital, Electronic Science and Technology University
| | - Xiangrui Wang
- Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University
| | - Hasan Babazada
- Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania
| | | | - Renyu Liu
- Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania
| | - Weifeng Yu
- Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University
| |
Collapse
|
14
|
Betti C, Starnowska J, Mika J, Dyniewicz J, Frankiewicz L, Novoa A, Bochynska M, Keresztes A, Kosson P, Makuch W, Van Duppen J, Chung NN, Vanden Broeck J, Lipkowski AW, Schiller PW, Janssens F, Ceusters M, Sommen F, Meert T, Przewlocka B, Tourwé D, Ballet S. Dual Alleviation of Acute and Neuropathic Pain by Fused Opioid Agonist-Neurokinin 1 Antagonist Peptidomimetics. ACS Med Chem Lett 2015; 6:1209-14. [PMID: 26713106 DOI: 10.1021/acsmedchemlett.5b00359] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2015] [Accepted: 10/31/2015] [Indexed: 02/08/2023] Open
Abstract
Herein, the synthesis and biological evaluation of dual opioid agonists-neurokinin 1 receptor (NK1R) antagonists is described. In these multitarget ligands, the two pharmacophores do not overlap, and this allowed maintaining high NK1R affinity and antagonist potency in compounds 12 and 13. Although the fusion of the two ligands resulted in slightly diminished opioid agonism at the μ- and δ-opioid receptors (MOR and DOR, respectively), as compared to the opioid parent peptide, balanced MOR/DOR activities were obtained. Compared to morphine, compounds 12 and 13 produced more potent antinociceptive effects in both acute (tail-flick) and neuropathic pain models (von Frey and cold plate). Similarly to morphine, analgesic tolerance developed after repetitive administration of these compounds. To our delight, compound 12 did not produce cross-tolerance with morphine and high antihyperalgesic and antiallodynic effects could be reinstated after chronic administration of each of the two compounds.
Collapse
Affiliation(s)
- Cecilia Betti
- Department
of Organic Chemistry, Vrije Universiteit Brussel, Brussels, Belgium
| | - Joanna Starnowska
- Institute
of Pharmacology, Polish Academy of Sciences, Kraków, Poland
| | - Joanna Mika
- Institute
of Pharmacology, Polish Academy of Sciences, Kraków, Poland
| | - Jolanta Dyniewicz
- Neuropeptide
Laboratory, Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland
| | - Lukasz Frankiewicz
- Department
of Organic Chemistry, Vrije Universiteit Brussel, Brussels, Belgium
| | - Alexandre Novoa
- Department
of Organic Chemistry, Vrije Universiteit Brussel, Brussels, Belgium
| | - Marta Bochynska
- Neuropeptide
Laboratory, Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland
| | - Attila Keresztes
- Department
of Pharmacology, University of Arizona, Tucson, Arizona 85721, United States
| | - Piotr Kosson
- Neuropeptide
Laboratory, Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland
| | - Wioletta Makuch
- Institute
of Pharmacology, Polish Academy of Sciences, Kraków, Poland
| | - Joost Van Duppen
- Animal
Physiology and Neurobiology Department, Katholieke Universiteit Leuven (KU Leuven), Leuven, Belgium
| | - Nga. N. Chung
- Department
of Chemical Biology and Peptide Research, Clinical Research Institute of Montreal, Montreal, Canada
| | - Jozef Vanden Broeck
- Animal
Physiology and Neurobiology Department, Katholieke Universiteit Leuven (KU Leuven), Leuven, Belgium
| | - Andrzej W. Lipkowski
- Neuropeptide
Laboratory, Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland
| | - Peter W. Schiller
- Department
of Chemical Biology and Peptide Research, Clinical Research Institute of Montreal, Montreal, Canada
| | - Frans Janssens
- Janssen Research & Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium
| | - Marc Ceusters
- Janssen Research & Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium
| | - François Sommen
- Janssen Research & Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium
| | - Theo Meert
- Janssen Research & Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium
| | | | - Dirk Tourwé
- Department
of Organic Chemistry, Vrije Universiteit Brussel, Brussels, Belgium
| | - Steven Ballet
- Department
of Organic Chemistry, Vrije Universiteit Brussel, Brussels, Belgium
| |
Collapse
|
15
|
Abstract
G protein-coupled receptors (GPCRs) compose one of the largest families of membrane proteins involved in intracellular signaling. They are involved in numerous physiological and pathological processes and are prime candidates for drug development. Over the past decade, an increasing number of studies have reported heteromerization between GPCRs. Many investigations in heterologous systems have provided important indications of potential novel pharmacology; however, the physiological relevance of these findings has yet to be established with endogenous receptors in native tissues. In this review, we focus on family A GPCRs and describe the techniques and criteria to assess their heteromerization. We conclude that advances in approaches to study receptor complex functionality in heterologous systems, coupled with techniques that enable specific examination of native receptor heteromers in vivo, are likely to establish GPCR heteromers as novel therapeutic targets.
Collapse
Affiliation(s)
- Ivone Gomes
- Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY 10029;
| | - Mohammed Akli Ayoub
- Biologie et Bioinformatique des Systèmes de Signalisation (BIOS) Group, INRA, UMR85, Unité Physiologie de la Reproduction et des Comportements; CNRS, UMR7247, F-37380 Nouzilly, France
- LE STUDIUM Loire Valley Institute for Advanced Studies, F-45000 Orleans, France
| | - Wakako Fujita
- Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY 10029;
- Current address: Department of Frontier Life Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8588, Japan
| | - Werner C Jaeger
- Molecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research, Nedlands, Western Australia 6009, Australia
- Centre for Medical Research, The University of Western Australia, Crawley, Western Australia 6009, Australia
| | - Kevin D G Pfleger
- Molecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research, Nedlands, Western Australia 6009, Australia
- Centre for Medical Research, The University of Western Australia, Crawley, Western Australia 6009, Australia
- Dimerix Bioscience Limited, Nedlands, Western Australia 6009, Australia
| | - Lakshmi A Devi
- Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY 10029;
| |
Collapse
|
16
|
Fujita W, Gomes I, Devi LA. Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10. Br J Pharmacol 2015; 171:4155-76. [PMID: 24916280 DOI: 10.1111/bph.12798] [Citation(s) in RCA: 68] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2013] [Revised: 01/27/2014] [Accepted: 04/16/2014] [Indexed: 12/24/2022] Open
Abstract
GPCRs can interact with each other to form homomers or heteromers. Homomers involve interactions with the same receptor type while heteromers involve interactions between two different GPCRs. These receptor-receptor interactions modulate not only the binding but also the signalling and trafficking properties of individual receptors. Opioid receptor heteromerization has been extensively investigated with the objective of identifying novel therapeutic targets that are as potent as morphine but without the side effects associated with chronic morphine use. In this context, studies have described heteromerization between the different types of opioid receptors and between opioid receptors and a wide range of GPCRs including adrenoceptors, cannabinoid, 5-HT, metabotropic glutamate and sensory neuron-specific receptors. Recent advances in the field involving the generation of heteromer-specific reagents (antibodies or ligands) or of membrane-permeable peptides that disrupt the heteromer interaction are helping to elucidate the physiological role of opioid receptor heteromers and the contribution of the partner receptor to the side effects associated with opioid use. For example, studies using membrane-permeable peptides targeting the heteromer interface have implicated μ and δ receptor heteromers in the development of tolerance to morphine, and heteromers of μ and gastrin-releasing peptide receptors in morphine-induced itch. In addition, a number of ligands that selectively target opioid receptor heteromers exhibit potent antinociception with a decrease in the side effects commonly associated with morphine use. In this review, we summarize the latest findings regarding the biological and functional characteristics of opioid receptor heteromers both in vitro and in vivo.
Collapse
Affiliation(s)
- Wakako Fujita
- Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | | | | |
Collapse
|
17
|
Bird MF, Vardanyan RS, Hruby VJ, Calò G, Guerrini R, Salvadori S, Trapella C, McDonald J, Rowbotham DJ, Lambert DG. Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands. Br J Anaesth 2015; 114:646-56. [PMID: 25680364 DOI: 10.1093/bja/aeu454] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
BACKGROUND Opioid tolerance is a limiting factor in chronic pain. Delta opioid peptide (DOP)(δ) receptor antagonism has been shown to reduce tolerance. Here, the common clinical mu opioid peptide (MOP)(µ) receptor agonist fentanyl has been linked to the DOP antagonist Dmt-Tic (2',6'-dimethyl-L-tyrosyl-1,2,3,4-tetrahydrisoquinoline-3-carboxylic acid) to create new bivalent compounds. METHODS Binding affinities of bivalents(#9, #10, #11, #12 and #13) were measured in Chinese hamster ovary (CHO) cells expressing recombinant human MOP, DOP, Kappa opioid peptide (KOP)(κ) and nociceptin/orphanin FQ opioid peptide (NOP) receptors. Functional studies, measuring GTPγ[(35)S] or β-arrestin recruitment, were performed in membranes or whole cells respectively expressing MOP and DOP. RESULTS The new bivalents bound to MOP (pKi : #9:7.31; #10:7.58; #11:7.91; #12:7.94; #13:8.03) and DOP (#9:8.03; #10:8.16; #11:8.17; #12:9.67; #13:9.71). In GTPγ[(35)S] functional assays, compounds #9(pEC50:6.74; intrinsic activity:0.05) #10(7.13;0.34) and #11(7.52;0.27) showed weak partial agonist activity at MOP. Compounds #12 and #13, with longer linkers, showed no functional activity at MOP. In antagonist assays at MOP, compounds #9 (pKb:6.87), #10(7.55) #11(7.81) #12(6.91) and #13(7.05) all reversed the effects of fentanyl. At DOP, all compounds showed antagonist affinity (#9:6.85; #10:8.06; #11:8.11; #12:9.42; #13:9.00), reversing the effects of DPDPE ([D-Pen(2,5)]enkephalin). In β-arrestin assays, compared with fentanyl (with response at maximum concentration (RMC):13.62), all compounds showed reduced ability to activate β-arrestin (#9 RMC:1.58; #10:2.72; #11:2.40; #12:1.29; #13:1.58). Compared with fentanyl, the intrinsic activity was: #9:0.12; #10:0.20; #11:0.18; #12:0.09 and #13:0.12. CONCLUSIONS The addition of a linker between fentanyl and Dmt-Tic did not alter the ability to bind to MOP and DOP, however a substantial loss in MOP functional activity was apparent. This highlights the difficulty in multifunctional opioid development.
Collapse
Affiliation(s)
- M F Bird
- Department of Cardiovascular Sciences, Division of Anaesthesia, Critical Care and Pain Management, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK
| | - R S Vardanyan
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, USA
| | - V J Hruby
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, USA
| | - G Calò
- Department of Medical Sciences, Section of Pharmacology, University of Ferrara and Italian Institute of Neuroscience, Ferrara, Italy
| | - R Guerrini
- Department of Chemical and Pharmaceutical Sciences and LTTA (Laboratorio per le Tecnologie delle Terapie Avanzate), University of Ferrara, Ferrara, Italy
| | - S Salvadori
- Department of Chemical and Pharmaceutical Sciences and LTTA (Laboratorio per le Tecnologie delle Terapie Avanzate), University of Ferrara, Ferrara, Italy
| | - C Trapella
- Department of Chemical and Pharmaceutical Sciences and LTTA (Laboratorio per le Tecnologie delle Terapie Avanzate), University of Ferrara, Ferrara, Italy
| | - J McDonald
- Department of Cardiovascular Sciences, Division of Anaesthesia, Critical Care and Pain Management, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK
| | - D J Rowbotham
- Department of Cardiovascular Sciences, Division of Anaesthesia, Critical Care and Pain Management, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK
| | - D G Lambert
- Department of Cardiovascular Sciences, Division of Anaesthesia, Critical Care and Pain Management, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK
| |
Collapse
|
18
|
Vardanyan RS, Hruby VJ. Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications. Future Med Chem 2014; 6:385-412. [PMID: 24635521 PMCID: PMC4137794 DOI: 10.4155/fmc.13.215] [Citation(s) in RCA: 158] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Fentanyl and its analogs have been mainstays for the treatment of severe to moderate pain for many years. In this review, we outline the structural and corresponding synthetic strategies that have been used to understand the structure-biological activity relationship in fentanyl-related compounds and derivatives and their biological activity profiles. We discuss how changes in the scaffold structure can change biological and pharmacological activities. Finally, recent efforts to design and synthesize novel multivalent ligands that act as mu and delta opioid receptors and NK-1 receptors are discussed.
Collapse
MESH Headings
- Analgesics, Opioid/chemical synthesis
- Analgesics, Opioid/chemistry
- Analgesics, Opioid/therapeutic use
- Animals
- Fentanyl/chemical synthesis
- Fentanyl/chemistry
- Fentanyl/therapeutic use
- Humans
- Neuralgia/drug therapy
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/metabolism
- Structure-Activity Relationship
Collapse
Affiliation(s)
- Ruben S Vardanyan
- Department of Chemistry & Biochemistry, University of Arizona, Tucson, AZ 85721, USA
| | - Victor J Hruby
- Department of Chemistry & Biochemistry, University of Arizona, Tucson, AZ 85721, USA
| |
Collapse
|
19
|
Bornot A, Bauer U, Brown A, Firth M, Hellawell C, Engkvist O. Systematic Exploration of Dual-Acting Modulators from a Combined Medicinal Chemistry and Biology Perspective. J Med Chem 2013; 56:1197-210. [DOI: 10.1021/jm301653f] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Aurelie Bornot
- Discovery Sciences, Computational Biology, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K
| | - Udo Bauer
- iMED CV/GI, Medicinal Chemistry, AstraZeneca R&D, Pepparedsleden 1, Mölndal, SE-431 83, Sweden
| | - Alastair Brown
- iMED CV/GI, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K
| | - Mike Firth
- Discovery Sciences, Computational Biology, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K
| | - Caroline Hellawell
- Discovery Sciences, Computational Biology, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K
| | - Ola Engkvist
- Discovery Sciences, Computational Chemistry, AstraZeneca R&D, Pepparedsleden 1, Mölndal, SE-431 83, Sweden
| |
Collapse
|
20
|
Abstract
This paper is the thirty-fourth consecutive installment of the annual review of research concerning the endogenous opioid system. It summarizes papers published during 2011 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides, opioid receptors, opioid agonists and opioid antagonists. The particular topics that continue to be covered include the molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors related to behavior (Section 2), and the roles of these opioid peptides and receptors in pain and analgesia (Section 3); stress and social status (Section 4); tolerance and dependence (Section 5); learning and memory (Section 6); eating and drinking (Section 7); alcohol and drugs of abuse (Section 8); sexual activity and hormones, pregnancy, development and endocrinology (Section 9); mental illness and mood (Section 10); seizures and neurologic disorders (Section 11); electrical-related activity and neurophysiology (Section 12); general activity and locomotion (Section 13); gastrointestinal, renal and hepatic functions (Section 14); cardiovascular responses (Section 15); respiration (Section 16); and immunological responses (Section 17).
Collapse
Affiliation(s)
- Richard J Bodnar
- Department of Psychology and Neuropsychology Doctoral Sub-Program, Queens College, City University of New York, Flushing, NY 11367, United States.
| |
Collapse
|
21
|
Haghighatnia Y, Balalaie S, Bijanzadeh HR. Designing and Synthesis of Novel Amidated Fentanyl Analogs. Helv Chim Acta 2012. [DOI: 10.1002/hlca.201100392] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|